email article Now that Johnson & Johnson has joined Pfizer and Moderna in having a COVID-19 vaccine authorized in the U.S., the question on many people's minds is: who gets which vaccine? Much of the discussion has focused on the differing vaccine efficacy numbers for the three products: those given for the J&J vaccine are in the 70% range, versus more than 90% for Pfizer's and Moderna's. But the Biden administration and independent public health specialists insist that those figures aren't strictly comparable and the public shouldn't pay much attention to them. Johnson & Johnson's "is not an inferior vaccine, and we should not talk about who shouldn't get it; we should talk about how we can immunize hard-to-get populations," said Sarah Long, MD, a pediatric diseases physician at Drexel University College of Medicine in Philadelphia and a member of the CDC's Advisory Committee on Immunization Practices (ACIP), during an emergency meeting of the committee Monday.